Article

Simple Salivary Signs Found for Sjögren Syndrome

Levels of β2 microglobulin and sodium in saliva distinguish patients with primary and secondary Sjögren syndrome from unaffected individuals.

Asashima H, Inokuma S, Onoda M et al.Cut-off levels of salivary beta2-microglobulin and sodium differentiating patients with Sjgren's syndrome from those without it and healthy controls.Clin Exp Rheumatol. (2013) Jun 26. [Epub ahead of print] PMID: 23806216
 

Levels of the biomarker β2 microglobulin (β2MG), a polypeptide found in saliva and serum, may be useful together with sodium (Na+) in identifying patients with Sjgren syndrome (SS), according to Japanese researchers.

Previous studies have shown β2MG in serum to be a marker for diagnosing and assessing disease activity in SS, and numerous studies have examined other candidate salivary biomarkers for the condition. But these authors say the diagnostic utility of β2MG and Na+ from saliva is not yet established.

Rheumatologists at the Japanese Red Cross Medical Center in Tokyo examined β2MG, Na+, Cl-, and potassium in whole unstimulated saliva from 71 primary Sjgren's (pSS) patients (the majority women with a median age of 60), 50 patients with secondary SS (sSS, also predominantly female), 54 people with connective tissue diseases unrelated to Sjgren syndrome, and 75 healthy controls.

In the SS group (both pSS and sSS), salivary levels of β2MG, Na+, and Cl- were significantly higher than in samples from the others. The cut-off levels that appear to differentiate SS patients from unaffected individuals are 2.3 mg/L for β MG and 23 mEq/L for Na+.

The hunt continues for other signs of the disease to be found in saliva. A multicenter observational trial of numerous salivary biomarkers for Sjgren syndrome sponsored by University of California Los Angeles, launched earlier this year, has not yet begun recruiting patients.
 

 

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
© 2024 MJH Life Sciences

All rights reserved.